EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Endothelial‐Derived CCL7 Promotes Macrophage Polarization and Aggravates Septic Acute Lung Injury via CCR1‐Mediated STAT1 Succinylation

Xue Li iD, Yuqin Long, Yunxi Zhu, Jiahui Gu, Ping Zhou, Changhong Miao iD

Advanced Science · 2025-10 · 12 (38)

DOI: 10.1002/advs.202506209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.08.2025. Verfasst von Xue Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Receptors, CCR1, Acute Lung Injury, Sepsis, Macrophages. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Clinical Research Center for Anesthesiology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute lung injury (ALI) is a significant complication of sepsis, wherein the interaction between pulmonary vascular endothelial cells and immune cells plays a pivotal role in the pathogenesis. In this study, it is demonstrated that secretion of chemokine C‐C motif ligand 7 (CCL7) by endothelial cells (ECs) induces metabolic reprogramming and M1 polarization of C‐C motif chemokine receptor 1‐positive (CCR1⁺) macrophages. It is noteworthy that mice with specific inhibition of endothelial‐derived CCL7 exhibit reduced severity of septic ALI, underscoring the critical role of CCL7 in the progression of sepsis. Mechanistically, activation of the CCL7–CCR1 axis enhances STAT1 succinylation through upregulation of KAT2A expression, leading to increased STAT1 binding to the promoter of glycolytic genes in macrophages. This epigenetic regulation modulates metabolic reprogramming and M1 polarization of macrophages, thereby driving inflammatory cascades in septic ALI. Furthermore, in sepsis models, Ccr1‐knockout (Ccr1 ‐KO ) mice demonstrate attenuated lung inflammation and decreased mortality, highlighting the therapeutic potential of targeting the CCL7–CCR1 axis for the treatment of septic ALI. Collectively, findings provide novel insights into the metabolic reprogramming of macrophages and identify the CCL7–CCR1 axis as a promising therapeutic target for septic ALI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR1Acute Lung InjurySepsisMacrophagesChemokine CCL7STAT1 Transcription FactorEndothelial CellsAnimalsMiceMice, KnockoutMice, Inbred C57BLHumansDisease Models, AnimalMale

Stichwörter der Autor:innen

CCL7glycolysismacrophagesepsissuccinylation

Substanzen

Receptors, CCR1Ccr1 protein, mouseChemokine CCL7STAT1 Transcription FactorStat1 protein, mouseCcl7 protein, mouse

Autor:innen und Institutionen

  • Department of Anesthesiology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Shanghai Key Laboratory of Perioperative Stress and Protection, Shanghai, China.

ORCID-Profile: Xue Li, Changhong Miao

Förderung

  • National Natural Science Foundation of China
  • Shanghai Clinical Research Center for Anesthesiology

Zitieren

APA

Li, X., Long, Y., Zhu, Y., Gu, J., Zhou, P., & Miao, C. (2025). Endothelial‐Derived CCL7 Promotes Macrophage Polarization and Aggravates Septic Acute Lung Injury via CCR1‐Mediated STAT1 Succinylation. Advanced Science, 12(38). https://doi.org/10.1002/advs.202506209

Vancouver

Li X, Long Y, Zhu Y, Gu J, Zhou P, Miao C. Endothelial‐Derived CCL7 Promotes Macrophage Polarization and Aggravates Septic Acute Lung Injury via CCR1‐Mediated STAT1 Succinylation. Advanced Science. 2025;12(38). doi:10.1002/advs.202506209

BibTeX
@article{Li2025,
  author = {Li, Xue and Long, Yuqin and Zhu, Yunxi and Gu, Jiahui and Zhou, Ping and Miao, Changhong},
  title = {Endothelial‐Derived CCL7 Promotes Macrophage Polarization and Aggravates Septic Acute Lung Injury via CCR1‐Mediated STAT1 Succinylation},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {38},
  doi = {10.1002/advs.202506209}
}
Kostenlos starten →